30th, March 2021

Lindal Press Release

LINDAL Group creates a new and stand-alone provider of spray packaging solutions for pharmaceutical applications. The new company RxPack is established together with Coster Group. RxPack will unlock value for its customers with a distinctive product offering and tap the growth opportunities in the regulated and non-regulated pharmaceutical sectors.

The new company RxPack (pronounced R-x-Pack) will include the highly complementary product lines from LINDAL and Coster for spray packaging solutions for pharmaceutical applications. RxPack will be among the only suppliers that offer both pulmonary inhalation devices such as aerosol MDIs and nasal pumps as well as other aerosol and dispensing solutions for the regulated and non-regulated pharmaceutical sectors. These technologies provide the most efficient and cost-effective way to treat respiratory diseases via inhaled drug delivery. RxPack’s packaging solutions offering will be supplemented with the corresponding aerosol filling machinery for the pharmaceutical sector, forming a distinctive and highly competitive product portfolio. RxPack will thus provide even better responses to its customers’ needs.

RxPack will operate from the current facility of LINDAL’s pharmaceutical business in Oggiono, north of Milan in Italy. It is expected to enter business by the end of this year, after the approval from the relevant authorities. LINDAL and Coster will each have an equal share in RxPack.

“RxPack is being established to take our pharmaceutical business to the next level and to create momentum in the pharmaceutical packaging sector”, says Katharina Lilienthal, Chairwoman of the Board of LINDAL and representative of the LINDAL shareholder family. “With its distinctive product portfolio and its strong financial resources, RxPack is ideally positioned to grow in the non-regulated sector and to enter the highly attractive regulated sector.”

RxPack starts from a position of strength

RxPack will start with a strong operational base. With the Oggiono site, it will be able to use the existing production facility already focused on the pharmaceutical business. The site offers excellent working and production conditions including the required cleanrooms and laboratories and the opportunity to build further capabilities to serve the pharmaceutical sector. RxPack will start its operations with approximately 60 employees, most of whom are transferring from LINDAL and all of whom have previously worked in the pharmaceutical business. Furthermore, RxPack will hire additional industry experts to further strengthen the organization.

An initial investment of four million EUR has been allocated for upgrading and extending clean room manufacturing capabilities. Thereafter, further investments are planned to drive innovation and growth.

RxPack will operate completely independently

Outside of RxPack, LINDAL and Coster are competitors in numerous areas and will remain so. RxPack will therefore operate as a stand-alone entity that is completely independent from the two groups.

RxPack will solely focus on the pharmaceutical sector, a segment requiring specialist expertise and manufacturing technology, and thus on the production and distribution of products used exclusively in this sector. LINDAL, just like Coster, will continue to focus on its core business, serving customers in the personal care, home care, technical and industrial sectors. However, the BOV products manufactured by LINDAL and Coster will not be included in RxPack, as they are based on a different technology which is deployed in applications not only for the pharmaceutical industry, but also for many other sectors. LINDAL and Coster will both continue to offer BOV products, also for the pharmaceutical sector, and remain strong competitors in this area.

To ensure its independence, RxPack will have a fully autonomous organization with corresponding governance and separate facilities. The facility in Oggiono will be exclusively dedicated to RxPack. All other non-pharmaceutical activities at this location will therefore be relocated to other LINDAL facilities during a carefully managed transition period and traded by LINDAL in Italy via a new LINDAL site nearby Oggiono.

About LINDAL Group

LINDAL Group is a worldwide leader in the design, manufacture and sale of valves, actuators and spray caps used in aerosol products. The Hamburg, Germany-based company has more than 60 years of experience with innovative dispensing solutions for the cosmetics, household, pharmaceuticals, food and technical industries.

The LINDAL Group is represented by subsidiaries and licensees in more than 15 countries throughout Europe, Asia and The Americas. The company is renowned for its innovative designs, which deliver optimal functionality and return on investment. As a result, LINDAL packaging solutions are the choice of the world’s most prestigious and trusted brands.

Coster Press Release

Coster Group transfers its pharmaceutical aerosol and dispensing business to the newly formed company RxPack. The new company combines Coster’s products and complementary offerings from Lindal Group to create a distinctive portfolio of spray packaging solutions for pharmaceutical applications. It is thus ideally positioned from the start to seize the growth opportunities in this sector. RxPack will be located in Oggiono, north of Milan in Italy, and is expected to start operations at the end of this year.

With RxPack (pronounced R-x-Pack), there will be a new provider of pharmaceutical packaging solutions with a distinctive and highly competitive product portfolio. RxPack will be one of the three leading players in the sector, thus having the opportunity to stimulate momentum and drive innovation among all sector participants. This will greatly benefit pharmaceutical companies and their customers alike.

“Our goal is to create a new strong player in the field of packaging solutions for pharmaceutical applications. RxPack has the expertise, the products and the financial strength to provide our pharmaceutical customers with innovative solutions that significantly improve the health and lives of sick people”, explains Martina Segatta, Chair of the Board and majority shareholder of Coster. “With RxPack, we create a powerful setup dedicated to the pharmaceutical sector that will enable us to serve this mission excellently and make the most of the opportunities in this sector.”

RxPack combines pharmaceutical businesses

RxPack will combine the highly complementary product lines of Lindal and Coster with spray packaging solutions for pharmaceutical applications: pulmonary inhalation devices such as MDIs, nasal devices such as nasal pumps and other aerosol and dispensing solutions for the regulated and non-regulated pharmaceutical sectors. Additionally, RxPack will be the exclusive distribution channel for Coster’s aerosol filling machines for pharmaceutical applications, excluding BOVs.

RxPack will start its business with about 60 employees of Coster and Lindal who bring special expertise for the pharmaceutical business. Furthermore, the company will hire additional specialized employees that are critical to the company’s success. The staff will be located at the production facility of Lindal in Oggiono which offers excellent working and production conditions including cleanrooms and laboratories.

Owner families are the driving forces behind the new company

Coster and Lindal will initially invest four million EUR in upgrading and extending clean room manufacturing capabilities. Further investments and R&D plans will target entering the highly attractive regulated sector and extending the product portfolio with innovative alternative pharmaceutical packaging solutions.

RxPack’s investments and R&D plans also reflect the motivation of the owner families behind Coster and Lindal. Martina Segatta, just like Katharina Lilienthal, Chairwoman of the Board of Lindal, has been a strong supporter of the establishment of RxPack from the beginning and firmly endorses the substantial investments to expand the range of high-quality and innovative solutions for customers. Their companies, Coster and Lindal, will each have an equal share in RxPack.

RxPack will be a stand-alone company

Coster and Lindal will continue to be competitors outside of RxPack. The new company will therefore operate completely independent from both groups and with a stand-alone organization and separate facilities, as the Oggiono site will be exclusively dedicated to RxPack. RxPack will solely focus on the pharmaceutical sector, a segment requiring special expertise and manufacturing technology, and thus on the production and distribution of products used exclusively targeting this sector.

Coster and Lindal will focus on their core business, serving customers in the personal care, home care, technical and industrial sectors. The manufacturing of the BOV products, however, will remain at Coster and Lindal. Since they are based on a different technology and address different segments in addition to the pharmaceutical sector, Lindal and Coster will both continue to offer BOV products, also for pharmaceutical applications, and remain strong competitors in this area.

About Coster Group

Coster Group is a multinational provider of spray packaging solutions and aerosol filling equipment. The company is family owned and was founded in 1963 in Italy, employing nowadays 1,000 employees and generating annual revenues above EUR 200M. It addresses all segments of the market with a complete range of aerosol valves and actuators, spray pumps, dispensers and anodizing solutions and has a global production network spread across four continents. The growth plan of Coster is based on sustainability and innovation, with the main ambition to provide the market with sustainable dispensing packaging solutions. The company is the world’s only supplier of both aerosol packaging components and filling machinery.